Globally, liver disease accounts for around two million deaths per year, with around one million of those due to cirrhosis and one million due to viral hepatitis and hepatocellular carcinoma.1 For decades, liver biopsy has been the conventional method for disease assessment, and more recently MR Proton Density Fat Fraction (MR-PDFF) has been added to measure liver fat. Today, ultrasound provides a noninvasive, accessible alternative to these methods.